GAIN THERAPEUTICS, INC Stock-Based Compensation
GAIN THERAPEUTICS, INC (GANX) reported Stock-Based Compensation of $969.56 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $566.05K, a 8.43% increase year-over-year.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $403.51K, a 3.81% decline year-over-year.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $401.67K, a 11.78% increase year-over-year.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $460.00K, a 28.67% increase year-over-year.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for fiscal 2025 was $1.80M, a 24.56% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for fiscal 2024 was $2.39M, a 26.66% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for fiscal 2023 was $3.26M, a 113.51% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC share-based payment arrangement, noncash expense for fiscal 2022 was $1.53M, a 81.85% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $566.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $969.56K 10-Q · filed 2026-08-11 | $1.37M derived: sum of 3 quarters · filed 2026-08-11 | $1.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $403.51K 10-Q · filed 2026-05-11 | $805.18K derived: sum of 2 quarters · filed 2026-05-11 | $1.27M derived: sum of 3 quarters · filed 2026-05-11 | $1.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $401.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $861.67K derived: sum of 2 quarters · filed 2026-03-26 | $1.38M derived: sum of 3 quarters · filed 2026-08-11 | $1.80M 10-K · filed 2026-03-26 |
| 2025-09-30 | $460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $982.02K derived: sum of 2 quarters · filed 2026-08-11 | $1.40M 10-Q · filed 2025-11-12 | $1.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $522.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $941.52K 10-Q · filed 2026-08-11 | $1.30M derived: sum of 3 quarters · filed 2026-08-11 | $1.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $419.50K 10-Q · filed 2026-05-11 | $778.83K derived: sum of 2 quarters · filed 2026-05-11 | $1.14M derived: sum of 3 quarters · filed 2026-05-11 | $2.62M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $359.33K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $716.83K derived: sum of 2 quarters · filed 2026-03-26 | $2.20M derived: sum of 3 quarters · filed 2026-03-26 | $2.39M 10-K · filed 2026-03-26 |
| 2024-09-30 | $357.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.84M derived: sum of 2 quarters · filed 2025-11-12 | $2.03M 10-Q · filed 2025-11-12 | $2.59M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.67M 10-Q · filed 2025-08-12 | $2.23M derived: sum of 3 quarters · filed 2025-08-12 | $3.14M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $190.42K 10-Q · filed 2025-05-14 | $745.48K derived: sum of 2 quarters · filed 2025-05-14 | $1.65M derived: sum of 3 quarters · filed 2025-05-14 | $2.88M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $555.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.46M derived: sum of 2 quarters · filed 2025-03-27 | $2.69M derived: sum of 3 quarters · filed 2025-03-27 | $3.26M 10-K · filed 2025-03-27 |
| 2023-09-30 | $907.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.14M derived: sum of 2 quarters · filed 2024-11-14 | $2.70M 10-Q · filed 2024-11-14 | $3.26M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.80M 10-Q · filed 2024-08-08 | $2.36M derived: sum of 3 quarters · filed 2024-08-08 | $2.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $565.43K 10-Q · filed 2024-05-14 | $1.12M derived: sum of 2 quarters · filed 2024-05-14 | $1.48M derived: sum of 3 quarters · filed 2024-05-14 | $1.79M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $558.69K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $914.34K derived: sum of 2 quarters · filed 2024-03-26 | $1.22M derived: sum of 3 quarters · filed 2024-03-26 | $1.53M 10-K · filed 2024-03-26 |
| 2022-09-30 | $355.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $661.20K derived: sum of 2 quarters · filed 2023-11-14 | $967.74K 10-Q · filed 2023-11-14 | $1.25M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $305.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $612.10K 10-Q · filed 2023-08-10 | $898.36K derived: sum of 3 quarters · filed 2023-08-10 | $1.15M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $306.55K 10-Q · filed 2023-05-12 | $592.80K derived: sum of 2 quarters · filed 2023-05-12 | $843.63K derived: sum of 3 quarters · filed 2023-05-12 | $1.04M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $286.26K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $537.09K derived: sum of 2 quarters · filed 2023-03-23 | $728.65K derived: sum of 3 quarters · filed 2023-03-23 | $839.37K 10-K · filed 2023-03-23 |
| 2021-09-30 | $250.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $442.39K derived: sum of 2 quarters · filed 2022-11-10 | $553.11K 10-Q · filed 2022-11-10 | $630.54K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $191.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $302.29K 10-Q · filed 2022-08-08 | $379.71K derived: sum of 3 quarters · filed 2022-08-08 | |
| 2021-03-31 | $110.72K 10-Q · filed 2022-05-16 | $188.15K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $77.43K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $81.64K 10-K · filed 2022-03-25 | ||
| 2020-09-30 | $4.21K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |